Medication-Assisted Treatment (MAT)

FDA lists three medications for opioid use disorder: buprenorphine, methadone, and naltrexone. The correct product and treatment setting depend on your health, recent substance use, other medicines, preferences, and ability to attend appointments.

Ask: What condition are we treating? What improvement are we looking for? How will we review side effects and ongoing cravings? Who should I contact before a missed appointment becomes a medication gap?

Counseling and practical support can be valuable parts of care. SAMHSA says inability to obtain counseling, or refusal of counseling, should not prevent buprenorphine prescribing. Its current OTP rules also do not make a patient’s refusal of counseling a reason to deny MOUD.

Buprenorphine is a partial opioid agonist. Suboxone film contains buprenorphine and naloxone; it is not the name of every buprenorphine product. Other products include tablets and long-acting injections. Ask the prescriber and pharmacy to confirm the exact medicine and formulation.

Buprenorphine can cause drowsiness and serious breathing problems, particularly with alcohol or other sedating substances. Its ceiling effect does not make misuse or combinations safe. Starting it at the wrong point in opioid use can trigger withdrawal; get an individual starting plan instead of using a website countdown.

Ask about other prescriptions, alcohol or sedative use, pregnancy, safe storage, driving, and what to do after a missed dose. Tell the clinician about medicines taken as prescribed as well as nonprescribed substances. Do not change prescribed medicines on your own to avoid a drug test.

For ongoing outpatient opioid-use-disorder treatment, methadone is generally provided through a certified opioid treatment program (OTP). A prescription for pain is a different situation. Ask an OTP about assessment, dispensing, transportation, and how it handles interruptions or transfers.

The federal rules revised in 2024 allow a clinician to consider some take-home medication upon entry into treatment. They do not impose a universal one-year wait. A take-home supply is an individualized decision, subject to safety assessment and state rules; it is not a guaranteed entitlement to a particular number of doses.

Ask: How often would I need to attend initially? What could change that schedule? What storage is required? What happens on weekends, during work travel, or after a missed visit? Methadone can cause dangerous breathing problems and drug interactions; do not add an extra dose because one was missed or seems ineffective.

Vivitrol is an extended-release naltrexone injection given by a healthcare professional. Its labeling covers alcohol dependence and prevention of relapse to opioid dependence after detoxification. It does not treat alcohol withdrawal.

Vivitrol can precipitate severe opioid withdrawal. Its label recommends at least 7–10 opioid-free days for people previously dependent on short-acting opioids and warns that transitions from buprenorphine or methadone can remain vulnerable for up to two weeks. Those intervals are not personal clearance: a clinician must assess the transition, and a negative urine screen does not eliminate the risk.

Trying to overcome the blockade can cause a fatal overdose. Risk also increases as a dose wears off, after a missed injection, or after treatment stops because opioid tolerance may be lower. Discuss overdose-reversal medication and a continuity plan. Vivitrol can cause dizziness or sleepiness; avoid driving until you know its effects. Review its full Medication Guide with your clinician.

NIAAA describes naltrexone, acamprosate, and disulfiram as FDA-approved options for alcohol use disorder. Naltrexone can reduce the urge to drink; acamprosate can support abstinence; disulfiram causes an adverse reaction when alcohol is consumed. These are different treatments, with different precautions.

Ask a clinician which option fits your treatment goal, medical history, kidney or liver concerns, other medicines, and recent opioid use. A medication for ongoing alcohol treatment is not a home-detox plan. If you may be physically dependent on alcohol, get medical help to plan withdrawal safely.

You do not need to find an “X-waivered” clinician. Federal law removed that special waiver requirement in December 2022. A buprenorphine prescriber still needs appropriate DEA registration and authority under applicable state law; “any licensed healthcare provider” is too broad.

SAMHSA announced that, beginning June 1, 2026, it is decommissioning the old waiver system and removing individual buprenorphine-practitioner search from FindTreatment.gov. Treatment facilities providing these medicines remain searchable. Start with a facility search, your usual clinician, or SAMHSA’s referral helpline, then confirm whether the provider is accepting patients and offers the medicine you need.

For telehealth, ask whether the clinician can treat a patient at your actual location, which visit format is permitted, and what in-person follow-up or pharmacy arrangements are needed. HHS describes the broad federal flexibility as temporarily extended through December 31, 2026. Do not assume that every remote prescription is permanently authorized or that an online service operates in every state.

Use the exact medication and formulation when asking about coverage. Confirm the clinician, dispensing pharmacy or OTP, injection administration if relevant, laboratory testing, counseling, and follow-up visits. A medication price alone may leave out other charges.

Ask your plan: Is this provider in network? Is this formulation covered? Is prior authorization needed? What deductible, copay, or coinsurance applies? If coverage is denied, request the written reason and the plan’s review or appeal instructions.

Without insurance, ask providers about sliding fees or funded treatment and what proof or eligibility review is required. Ask how long assistance lasts and what happens if it ends. A referral, Medicaid enrollment, or manufacturer assistance program does not by itself confirm a free appointment or the full cost of care.

Tests differ in which medicines they detect, their cutoffs, and whether an initial result is confirmed. A routine “opiates” screen does not detect every opioid. Buprenorphine and methadone have specific testing options; do not infer an individual result from a generic five-panel or extended-panel label.

Vivitrol’s label specifically warns about possible cross-reactivity with certain urine opioid immunoassays. It is incorrect to promise that naltrexone can never affect a screen. An unexpected screening result needs appropriate laboratory and clinical review.

Ask the testing program how to provide prescription information to its designated medical reviewer, what confirmatory testing is available, and how to dispute an inaccurate report. Use the program’s documented process and ask who receives the medical information. This page cannot predict a test result or excuse a supervision requirement.

DOJ’s ADA guidance, dated April 5, 2022, explains protections for people with opioid use disorder who are not currently engaging in illegal drug use. Taking medication as prescribed under professional supervision is not illegal drug use. The guidance includes an example of an unlawful blanket jail ban on prescribed MOUD.

A housing or supervision dispute needs review of the actual program, written restriction, and circumstances. Ask for the policy and denial in writing. Contact your treating clinician and lawyer or legal aid promptly about continuity of care and any appropriate accommodation or challenge. Do not change medication on your own or assume this guide cancels a court order.

For housing, ask about prescription storage, OTP transportation, admissions, and who can review a medication-related denial before paying a deposit or moving. Federal funding alone is not a reliable test of which legal protections apply. This guide does not determine whether a particular residence must admit you.

Write down the exact medicine, how you were instructed to take it, the next appointment, the dispensing location, and the number to use for side effects, missed doses, or supply problems. Ask how changes in work, housing, insurance, or supervision could affect access.

Treatment can continue for a long time when clinically appropriate. A date on a sobriety counter is not a reason to taper. Discuss any change with the treating clinician, including pain treatment or a hospital stay.

Ask how to obtain and use naloxone or another prescribed overdose-reversal medicine. If someone cannot be awakened or is breathing slowly or abnormally and opioid overdose is suspected, give naloxone if available, call 911, and stay with them until help arrives. Follow the product and emergency-dispatch instructions. A peer meeting or referral helpline cannot treat an overdose.